High Degree of Heterogeneity in Alzheimer's Disease Progression Patterns
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
There have been several reports on the varying rates of progression among Alzheimer's Disease (AD) patients; however, there has been no quantitative study of the amount of heterogeneity in AD. Obtaining a reliable quantitative measure of AD progression rates and their variances among the patients for each stage of AD is essential for evaluating results of any clinical study. The Global Deterioration Scale (GDS) and Functional Assessment Staging procedure (FAST) characterize seven stages in the course of AD from normal aging to severe dementia. Each GDS/FAST stage has a published mean duration, but the variance is unknown. We use statistical analysis to reconstruct GDS/FAST stage durations in a cohort of 648 AD patients with an average follow-up time of 4.78 years. Calculations for GDS/FAST stages 4-6 reveal that the standard deviations for stage durations are comparable with their mean values, indicating the presence of large variations in the AD progression among patients. Such amount of heterogeneity in the course of progression of AD is consistent with the existence of several sub-groups of AD patients, which differ by their patterns of decline.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD
Jack, C. R., Shiung, M. M., Gunter, J. L., O’Brien, P. C., Weigand, S. D., Knopman, D. S., Boeve, B. F., Ivnik, R. J., Smith, G. E., Cha, R. H., et al. (2004) · Neurology · doi:10.1212/01.wnl.0000110315.26026.ef · Cited by 827
Nestor, S. M., Rupsingh, R., Borrie, M., Smith, M., Accomazzi, V., Wells, J. L., Fogarty, J., Bartha, R., & Initiative, T. A. D. N. (2008) · Brain · doi:10.1093/brain/awn146 · Cited by 543
Morris, J. C., Edland, S., Clark, C., Galasko, D., Koss, E., Mohs, R., van Belle, G., Fillenbaum, G., & Heyman, A. (1993) · Neurology · doi:10.1212/wnl.43.12.2457 · Cited by 441
McEvoy, L. K., Fennema-Notestine, C., Roddey, J. C., Hagler, D. J., Holland, D., Karow, D. S., Pung, C. J., Brewer, J. B., & Dale, A. M. (2009) · Radiology · doi:10.1148/radiol.2511080924 · Cited by 330
Accelerated decline in apolipoprotein E-ϵ4 homozygotes with Alzheimer's disease
Craft, S., Teri, L., Edland, S. D., Kukull, W. A., Schellenberg, G., McCormick, W. C., Bowen, J. D., & Larson, E. B. (1998) · Neurology · doi:10.1212/wnl.51.1.149 · Cited by 152 · cited 1×
“While the biological correlates of this variability have been investigated by many groups [2–19], the underlying reasons for such variations remain largely uncertain.”
BackgroundCruchaga, C., Kauwe, J. S. K., Mayo, K., Spiegel, N., Bertelsen, S., Nowotny, P., Shah, A. R., Abraham, R., Hollingworth, P., Harold, D., et al. (2010) · PLoS Genetics · doi:10.1371/journal.pgen.1001101 · Cited by 128 · cited 1×
“In paper [37], heterogeneity of AD is related to genetic variation in patients, such as that associated with cerebrospinal fluid phospho-tau levels.”
BackgroundWhole-brain atrophy rate in Alzheimer disease: Identifying fast progressors
Sluimer, J. D., Vrenken, H., Blankenstein, M. A., Fox, N. C., Scheltens, P., Barkhof, F., & van der Flier, W. M. (2008) · Neurology · doi:10.1212/01.wnl.0000311446.61861.e3 · Cited by 110
Sabbagh, M. N., Cooper, K., DeLange, J., Stoehr, J. D., Thind, K., Lahti, T., Reisberg, B., Sue, L., Vedders, L., Fleming, S. R., et al. (2010) · Current Alzheimer Research · doi:10.2174/156720510791162340 · Cited by 79 · cited 1×
“The FAST stages have been enumerated to be concordant with the GDS stages from which they were derived [23], although some differences between the two scales have also been demonstrated [24].”
Result
Cited by
Inconsistencies and Controversies Surrounding the Amyloid Hypothesis of Alzheimer's Disease
Morris, G. P., Clark, I. A., & Vissel, B. (2014) · Acta Neuropathologica Communications · doi:10.1186/s40478-014-0135-5 · Cited by 522
Tau molecular diversity contributes to clinical heterogeneity in Alzheimer’s disease
Dujardin, S., Commins, C., Lathuiliere, A., Beerepoot, P., Fernandes, A. R., Kamath, T. V., De Los Santos, M. B., Klickstein, N., Corjuc, D. L., Corjuc, B. T., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0938-9 · Cited by 438
Sadick, J. S., O’Dea, M. R., Hasel, P., Dykstra, T., Faustin, A., & Liddelow, S. A. (2022) · Neuron · doi:10.1016/j.neuron.2022.03.008 · Cited by 415
The Amyloid Cascade Hypothesis in Alzheimer’s Disease: It’s Time to Change Our Mind
Ricciarelli, R., & Fedele, E. (2017) · Current Neuropharmacology · doi:10.2174/1570159x15666170116143743 · Cited by 380
“different ages, and with distinctive cognitive symptoms and disease progression [41-43].”
BackgroundDuara, R., & Barker, W. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01185-z · Cited by 187
Ma, M., Dorstyn, D., Ward, L., & Prentice, S. (2018) · Aging & Mental Health · doi:10.1080/13607863.2017.1370689 · Cited by 133
Gaikwad, S., Senapati, S., Haque, M. A., & Kayed, R. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13490 · Cited by 117
Heterogeneity of Alzheimer’s disease: consequence for drug trials?
Devi, G., & Scheltens, P. (2018) · Alzheimer's Research & Therapy · doi:10.1186/s13195-018-0455-y · Cited by 102
Shokouhi, S., Claassen, D., Kang, H., Ding, Z., Rogers, B., Mishra, A., Riddle, W. R., & Initiative, F. T. A. D. N. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.116137 · Cited by 54
“Test–retest reliability, learning effects, floor or ceiling effects, and variability in disease progression (5,6) can confound interpretation of these measures.”
BackgroundZaręba-Kozioł, M., Szwajda, A., Dadlez, M., Wysłouch-Cieszyńska, A., & Lalowski, M. (2014) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m113.036079 · Cited by 39
Tonga, J. B., Karlsoeen, B. B., Arnevik, E. A., Werheid, K., Korsnes, M. S., & Ulstein, I. D. (2016) · American Journal of Alzheimer's Disease & Other Dementias® · doi:10.1177/1533317515603958 · Cited by 11
Metadata
- Authors
- Komarova, N. L., & Thalhauser, C. J.
- Venue
- PLoS Computational Biology
- Publisher
- Public Library of Science (PLoS)
- Published
- 2011-11-03
- Volume
- 7
- Issue
- 11
- Pages
- e1002251
- ISSN
- 1553-734X (ISSN-L)
- 1553-7358
- OpenAlex
- W2026631096
- Cited by
- 91
- References
- 9
- FWCI
- 1.38
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.